

Table 4: Summary of adverse events

Adverse events	Studies reporting the adverse events	Event in ablation group	Event in CBA	Event in RFA	Event in AAM group	Studies available for analysis	OR (95%CI) or pooled OR (95%CI)*
Mortality	3	3/366	0/154	3/212	4/358	1	0.76(0.17 to 3.44)
Cerebrovascular accident	4	2/398	0/154	2/244	2/393	2	1.05 (0.15-7.19)
Pulmonary vein stenosis	3	4/244	N/A	4/244	0/244	3	3.74 (0.60-23.26)
Pericardial effusion or cardiac tamponade	4	8/470	1/154	7/316	2/457	4	2.50 (0.61-10.26)
Bradycardia	5	3/502	2/258	1/244	7/492	5	0.59 (0.17-2.04)
Syncope	3	1/324	1/258	0/66	6/309	3	0.28 (0.06-1.40)
Acute coronary syndrome	2	1/258	1/258	N/A	3/248	2	0.46 (0.06-3.57)
Deep vein thrombosis or pulmonary embolism	3	1/290	1/258	0/32	1/283	2	0.96 (0.10-9.29)
Hematoma	2	2/300	1/154	1/146	0/297	2	2.99 (0.31-28.92)
Phrenic nerve injury	1	3/154	3/154	N/A	0/149	1	6.91 (0.35-134.88)
Esophageal-related complication	2	2/220	2/154	0/66	1/210	1	1.95 (0.17-21.71)
Perforation	1	1/146	N/A	1/146	0/148	1	3.06 (0.12-75.78)

AAM: Anti-arrhythmic medication, CBA: Cryoballoon ablation, CI: Confidence interval, RFA: Radiofrequency ablation, N/A: Not applicable, OR: Odds ratio

*Odds of developing the complication in ablation group (both CBA and RFA) when compared to AAM group